Most Popular in the Last...

Home

Avanir Pharmaceuticals Inc

See the following -

Avanir Pharmaceuticals Announces Research Collaboration With Department Of Veterans Affairs For Screening Pseudobulbar Affect (PBA) Symptoms In Veterans With Traumatic Brain Injury

Press Release | Avanir Pharmaceuticals, Inc. | March 6, 2013

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) in collaboration with the Department of Veterans Affairs (VA) and United BioSource Corporation (UBC) today announced a pilot study to screen for pseudobulbar affect (PBA) symptoms in approximately 1,000 veterans with traumatic brain injury (TBI) . Read More »

Avanir Pharmaceuticals Presents Data From A Benchmark Study Of PBA Symptoms In Veterans With Mild Traumatic Brain Injury

Press Release | Avanir Pharmaceuticals, Inc. | March 19, 2014

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury (TBI) conducted in collaboration with the Department of Veterans Affairs (VA) and Evidera. Read More »